Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease - Episode 7

Approved Therapies for Steroid-Refractory Chronic GvHD

,

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Overview of Graft-vs-Host Disease (GvHD)
    EP. 2: How Does GvHD Typically Present?
    EP. 3: Role of Biomarkers in Graft-vs-Host Disease
    EP. 4: Staging Practices for Chronic Graft-vs-Host Disease
    EP. 5: First-Line Therapy for Chronic GvHD
    EP. 6: Treating Patients With Steroid-Refractory Chronic GvHD
    Now Viewing
    EP. 7: Approved Therapies for Steroid-Refractory Chronic GvHD
    EP. 8: Therapies in Development for Chronic GvHD
    EP. 9: Supportive Care and Medication Access in GvHD

    x